Anagenics (ASX:AN1) reported a revenue of AU$893,000 in the fiscal third quarter, falling from AU$1.3 million it reported in the fiscal second quarter, according to a Friday Australian bourse filing.
Its underlying net profit after tax came in at AU$138,000, down from AU$275,000 in the prior quarter.
It noted that its revenue and other income remained at 63% of the first fiscal quarter figures, following its recent restructuring. The decline in sales was attributed to the divestment of the Face MediGroup business. Sales during the quarter were also impacted by a one-off warehousing
transition from 3PL to an in-house service.
Following the restructuring, operating expenses have been recalibrated to 25% of fiscal Q1 levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.